CSLLY CSL Limited
Company Analysis
Latest News
CSL Appoints Deborah Waterhouse CEO, Effective February 1, 2027
CSL Limited has appointed Deborah Waterhouse as its Chief Executive Officer and Managing Director, effective February 1, 2027. She will succeed the current CEO...
CSL Taps AWS to Bring AI Into Drug Research and Clinical Trials
Australian biotechnology firm CSL has announced a collaboration with Amazon Web Services (AWS) to bring artificial intelligence and cloud technologies into its...
CSL Vows Performance Reset, Advances CEO Search After Disappointing Results
CSL Limited’s board admitted recent financial performance was disappointing in a statement before the annual general meeting. Chairman Brian McNamee confirmed...
CSL Validates Triple-Technology Flu Vaccine in Lancet, Boosting Senior Protection
CSL Seqirus published pivotal Phase 3 study results for its AUJEMFLU® quadrivalent influenza vaccine in The Lancet Infectious Diseases. The peer-reviewed data...
CSL shares rise on Trump administration drug pricing and manufacturing deals
CSL signed two agreements with the Trump administration covering drug pricing and U.S. manufacturing expansion. The company will align Medicaid drug prices...
🟢 CSL is trading 6% up today after underlying earnings beat and stronger FY2027 outlook
CSL is trading 6.01% up now at $29.79 as investors continued buying after the August 18 FY2026 results, where underlying earnings exceeded expectations. -...
🟢 CSL is trading 17.3% up today after underlying earnings beat expectations
CSL is trading 17.3% up at $28.10 after investors continued buying following August 18 FY2026 results. - Despite a $2.6 billion statutory loss from...
CSL Posts a $2.6 Billion Loss but Investors See a Turnaround — Is the Worst of the Vifor Hangover Finally Over?
Shares of CSL Limited surged nearly 16% on August 18 after the Australian biotech giant framed fiscal 2026 as a "reset year" and pointed investors toward...
🟢 CSL is trading 17% up today after better-than-expected FY26 underlying earnings
CSL is trading at $28.03 (+17.04%) after better-than-expected FY26 underlying earnings and approximately 5% FY27 underlying profit growth guidance. -...
CSL Limited Q2 2026 Earnings Preview: What Analysts Expect on August 17, 2026
For the fiscal year ending June 30, 2026, analysts expect CSL Limited to report full-year revenue of $16.32 billion and EPS of $6.65, with the current stock...